Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
136 participants
INTERVENTIONAL
2006-08-22
2007-10-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
[S,S]-Reboxetine + Pregabalin
[S,S]-Reboxetine + Pregabalin
\[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
Pregabalin
Pregabalin
Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[S,S]-Reboxetine + Pregabalin
\[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
Pregabalin
Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients at screening must have a score \>/=40 mm on the pain visual analogue scale
Exclusion Criteria
* Patients with other severe pain, that may impair the self-assessment of the pain due to shingles
* Patients with clinically abnormal electrocardiogram
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Huntsville, Alabama, United States
Pfizer Investigational Site
Gilbert, Arizona, United States
Pfizer Investigational Site
North Dartmouth, Massachusetts, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Amherst, New York, United States
Pfizer Investigational Site
Orchard Park, New York, United States
Pfizer Investigational Site
Kettering, Ohio, United States
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Kelowna, British Columbia, Canada
Pfizer Investigational Site
Langley, British Columbia, Canada
Pfizer Investigational Site
Greater Sudbury, Ontario, Canada
Pfizer Investigational Site
Greater Sudbury, Ontario, Canada
Pfizer Investigational Site
Hawkesbury, Ontario, Canada
Pfizer Investigational Site
North Bay, Ontario, Canada
Pfizer Investigational Site
Val Caron, Ontario, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Québec, Quebec, Canada
Pfizer Investigational Site
Saint Romuald, Quebec, Canada
Pfizer Investigational Site
Regina, Saskatchewan, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
Sasktatoon, Saskatchewan, Canada
Pfizer Investigational Site
České Budějovice, , Czechia
Pfizer Investigational Site
Pilsen, , Czechia
Pfizer Investigational Site
Erbach im Odenwald, , Germany
Pfizer Investigational Site
Hattingen, , Germany
Pfizer Investigational Site
Jena, , Germany
Pfizer Investigational Site
Karlsruhe, , Germany
Pfizer Investigational Site
Katzhütte, , Germany
Pfizer Investigational Site
Mainz, , Germany
Pfizer Investigational Site
Mainz, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Münster, , Germany
Pfizer Investigational Site
Wiesbaden, , Germany
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Napoli, , Italy
Pfizer Investigational Site
Perugia, , Italy
Pfizer Investigational Site
Riga, , Latvia
Pfizer Investigational Site
Breda, , Netherlands
Pfizer Investigational Site
Utrecht, , Netherlands
Pfizer Investigational Site
Bekkestua, , Norway
Pfizer Investigational Site
Lierskogen, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Sandnes, , Norway
Pfizer Investigational Site
Trondheim, , Norway
Pfizer Investigational Site
Krakow, , Poland
Pfizer Investigational Site
Poznan, , Poland
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Yaroslavl, , Russia
Pfizer Investigational Site
L'Hospitalet de Llobregat, Barcelona, Spain
Pfizer Investigational Site
Cadiz, , Spain
Pfizer Investigational Site
Granada, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Seville, , Spain
Pfizer Investigational Site
Valencia, , Spain
Pfizer Investigational Site
Eksjö, , Sweden
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Karlstad, , Sweden
Pfizer Investigational Site
Skellefteå, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Zurich, , Switzerland
Pfizer Investigational Site
Dnipropetrovsk, , Ukraine
Pfizer Investigational Site
Donetsk, , Ukraine
Pfizer Investigational Site
Kharkiv, , Ukraine
Pfizer Investigational Site
Kharkiv, , Ukraine
Pfizer Investigational Site
Kharkiv, , Ukraine
Pfizer Investigational Site
Kharkiv, , Ukraine
Pfizer Investigational Site
Kyiv, , Ukraine
Pfizer Investigational Site
Kyiv, , Ukraine
Pfizer Investigational Site
Odesa, , Ukraine
Pfizer Investigational Site
Simferopol, , Ukraine
Pfizer Investigational Site
Uzhhorod, , Ukraine
Pfizer Investigational Site
Portsmouth, Hampshire, United Kingdom
Pfizer Investigational Site
London, UK, United Kingdom
Pfizer Investigational Site
Birmingham, West Midlands, United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Manchester, , United Kingdom
Pfizer Investigational Site
Plymouth, , United Kingdom
Pfizer Investigational Site
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6061021
Identifier Type: -
Identifier Source: org_study_id